Compositions and methods for treating chronic inflammation and inflammatory diseases

Patent metadata

Field	Value
Publication number	US-10155042-B2
Application number	US-201715614592-A
Country	US
Kind code	B2
Filing date	Jun 5, 2017
Priority date	Oct 29, 2010
Publication date	Dec 18, 2018
Grant date	Dec 18, 2018

Abstract

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

First claim

The invention claimed is:

1. A method of treating an individual with a chronic inflammation, the method comprising the step of: administering to the individual in need thereof a pharmaceutical composition, the pharmaceutical composition comprising:
a) about 10% to 30% of a propionic derivative NSAID by weight of the pharmaceutical composition;
b) about 5% to about 15% of a polyethylene glycol (PEG) polymer by weight of the pharmaceutical composition, the pharmaceutically-acceptable PEG polymer being less than about 2,000 g/mol;
c) about 20% to about 50% of a hard fat by weight of the pharmaceutical composition, the hard fat comprising a triglyceride or a triester of glycerol; and
d) about 10% to about 30% of a liquid fat by weight of the pharmaceutical composition, the liquid fat comprising a monoglyceride,
wherein the pharmaceutical composition is formulated to be a solid at a temperature of about 15° C. or lower and have a melting point temperature in the range of about 25° C. or higher, and
wherein administration results in a reduction in a symptom associated with the chronic inflammation, thereby treating the individual.

2. The method according to claim 1 , wherein the propionic acid derivative NSAID is about 20% to about 30% by weight of the pharmaceutical composition.

3. The method according to claim 2 , wherein the propionic acid derivative NSAID is in an amount from about 25% to about 30% by weight of the pharmaceutical composition.

4. The method according to claim 1 , wherein the propionic acid derivative NSAID comprises an Alminoprofen, a Benoxaprofen, a Dexketoprofen, a Fenoprofen, a Flurbiprofen, an Ibuprofen, an Indoprofen, a Ketoprofen, a Loxoprofen, a Naproxen, an Oxaprozin, a Pranoprofen, or a Suprofen.

5. The method according to claim 1 , wherein the propionic acid derivative NSAID is a pharmaceutically-acceptable form of an Ibuprofen.

6. The method according to claim 1 , wherein the hard fat is in an amount from about 30% to about 50% by weight of the pharmaceutical composition.

7. The method according to claim 6 , wherein the hard fat is in an amount from about 35% to about 45% by weight of the pharmaceutical composition.

8. The method according to claim 1 , wherein the hard fat has a melting point of about 40° C. to about 46° C.

9. The method according to claim 8 , wherein the hard fat comprises a mixture of saturated C10-C18 triglycerides having a melting point of between 41° C. to 45° C.

10. The method according to claim 9 , wherein the hard fat comprises a mixture of saturated C10-C18 triglycerides having a melting point of about 43° C.

11. The method according to claim 1 , wherein the liquid fat is in an amount from about 15% to about 25% by weight of the pharmaceutical composition.

12. The method according to claim 1 , wherein the liquid fat further comprises a diglyceride, a triglyceride, or any combination thereof.

13. The method according to claim 1 , wherein the monoglyceride—is glyceryl monolinoleate.

14. The method according to claim 1 , wherein the PEG polymer is in an amount from about 8% to about 15% by weight of the pharmaceutical composition.

15. The method according to claim 14 , wherein the PEG polymer is in an amount from about 7% to about 13% by weight of the pharmaceutical composition.

16. The method according to claim 15 , wherein the pharmaceutically-acceptable PEG polymer is in an amount from about 8% to about 12% by weight of the pharmaceutical composition.

17. The method according to claim 16 wherein the PEG polymer is in an amount from about 9% to about 11% by weight of the pharmaceutical composition.

18. The method according to claim 1 , wherein administration is topical, enteral or parenteral.

19. The method according to claim 1 , wherein the chronic inflammation is a tissue inflammation or a systemic inflammation.

20. The method according to claim 1 , wherein the chronic inflammation is due to an auto-immune disease or a non-autoimmune disease.

Assignees

• Infirst Healthcare Ltd

Inventors

• Bannister Robin M
• Brew John
• Caparros-Wanderely Wilson
• Dilly Suzanne J
• Pleguezeulos Mateo Olga
• Stoloff Gregory A

Classifications

• A61K31/60

  Salicylic acid; Derivatives thereof · CPC title

• A61K9/08

  Solutions {(composition of solutions A61K47/00)} · CPC title

• A61K31/704

  attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} · CPC title

• A61K31/337

  having four-membered rings, e.g. taxol · CPC title

• A61K31/25

  with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol · CPC title